Tesla is actively involved infighting the COVID-19 pandemic. This fact is confirmed by Elon Musk, CEO and founder of a company specializing in the production of electric vehicles and solar power plants. Tesla, in partnership with German biotech company CureVac, is developing the third generation of an RNA vaccine printer. According to Musk, expressed on Twitter, this will be a fundamentally necessary product for the whole world.
Biotech firm CureVac is working ona vaccine to combat COVID-19 based on RNA technology. Automaker Tesla will manufacture the automated RNA printing system and promote its adoption worldwide.
RNA (ribonucleic acid) is a moleculefound in all forms of cell life. CureVac has developed a molecule stabilization technique to combat certain diseases in the body. The RNA-based CureVac vaccine is currently in its second phase of clinical trials. Previously, the CureVac company worked on the creation of various flu vaccines, but with the advent of COVID-19, it focused on solving the problem of combating the coronavirus.
The main problem in the case of clinical successtrials for the distribution of the RNA vaccine will be difficult to store at low temperatures. Therefore, it is fundamentally important to place the RNA printers created by Tesla, or "bioreactors for RNA", directly in the foci of the disease.
Musk recently visited Germany, after which heTweeted about work on a printer to create synthetic RNA. At the same time, he noted that this project will probably not affect the financial performance of Tesla, whose annual revenue is about $ 20 billion.